Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura

Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura

this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.

Inclusion Criteria Adult patients (≥18 years) diagnosed with primary ITP. Receiving eltrombopag as part of their treatment. Baseline liver function tests (LFTs) within normal limits. Patients with diabetes Patients without diabetes Patients with fatty liver Patients without fatty liver

Exclusion Criteria:

Pre-existing liver disease (e.g., hepatitis, cirrhosis, NAFLD). Concurrent use of hepatotoxic drugs. Patients lost to follow-up.